The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

French drugmaker Sanofi said the U.S. Food and Drug Administration ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

Sanofi will share recent clinical evidence reinforcing MenQuadfi’s best-in-class profile and unique ready-to-use syringe in the fight against meningitis. FDA submission of MenQuadfi first and only ...

While it’s largely preventable through vaccines such as Sanofi’s own MenQuadfi, infection of the most severe form, bacterial meningitis, can be fatal within just 24 hours and remains a ...

May 27 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against ...